{"id":35778,"date":"2023-06-07T13:45:41","date_gmt":"2023-06-07T13:45:41","guid":{"rendered":"https:\/\/www.idissc.org\/idissc-research-seminar-november22\/"},"modified":"2023-06-07T13:45:46","modified_gmt":"2023-06-07T13:45:46","slug":"idissc-research-seminar-november22","status":"publish","type":"page","link":"https:\/\/www.idissc.org\/en\/idissc-research-seminar-november22\/","title":{"rendered":"IdISSC Research Seminar – November’22"},"content":{"rendered":"\n

16 November 2022<\/strong><\/p>\n\n

Online modality<\/strong>: URL for accessing the seminars:\u00a0https:\/\/madrid.zoom.us\/j\/82112222618<\/a><\/p>\n\n

<\/p>\n\n

13:00h <\/strong><\/p>\n\n

Report on the scientific activity 2021 of the Health Research Institute of the Hospital Cl\u00ednico San Carlos<\/strong><\/p>\n\n

Dr. Elena Urcelay Garc\u00eda. Scientific Director of the Health Research Institute of the Hospital Cl\u00ednico San Carlos (IdISSC).<\/p>\n\n

This session will present the milestones of the scientific activity developed throughout the year 2021. It will highlight, among others, the bibliometric analysis data, research projects, and technology transfer and scientific dissemination activities.<\/p>\n\n

13:05 <\/strong>h<\/strong><\/p>\n\n

Dissemination FIBHCSC Nominative Grant 2022<\/strong><\/p>\n\n

Dr. Joana Modolell Aguilar. Director of the FIB-HCSC. Health Research Institute of the Hospital Cl\u00ednico San Carlos (IdISSC).<\/p>\n\n

The IdISSC scientific community will be presented with available information on the Nominative Grant for Biomedical Research Foundations of the Community of Madrid.<\/p>\n\n

It will detail the objectives, priorities and proposed expenditure execution for the Health Research Institute of the Hospital Cl\u00ednico San Carlos in 2022.<\/p>\n\n

<\/p>\n\n

13:10<\/strong> h<\/strong><\/p>\n\n

Effects of Intravenous Administration of Lysine Acetylsalicylate versus Oral Aspirin on Platelet Response in Patients with Acute ST-Segment Elevation Myocardial Infarction: a pharmacodynamic study.<\/p>\n\n

\"\"<\/figure>\n

Dr. Luis David Vivas Balcones<\/em><\/strong><\/p>\n\n

Specialist Cardiology Area Practitioner. Translational research group in acute myocardial syndromes. Health Research Institute of the Hospital Cl\u00ednico San Carlos (IdISSC).<\/p>\n\n

Background<\/em><\/strong>. Prasugrel and ticagrelor, new P2Y12-ADP receptor antagonists, are associated with greater pharmacodynamic inhibition and reduction of cardiovascular events in patients with an acute coronary syndrome. However, evidence is lacked about the effects of achieving faster and stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared to oral aspirin. Recently, we demonstrated in healthy volunteers that the administration of intravenous LA resulted in a significantly reduction of platelet reactivity compared to oral aspirin. Loading dose of LA achieves platelet inhibition faster, greater and with less variability than aspirin. However, there are no data of this issue in patients with an ST-segment elevation myocardial infarction (STEMI).<\/p>\n\n

Methods.<\/em><\/strong>\u00a0This is a prospective, randomized, multicenter, open platelet function study conducted in STEMI patients. Subjects were randomly assigned to receive a loading dose (LD) of intravenous LA 450mg plus oral ticagrelor 180mg, or LD of aspirin 300mg plus ticagrelor 180mg orally. Platelet function was evaluated at baseline, 30 min, 1h, 4h and 24h using multiple electrode aggregometry and vasodilator-stimulated phosphoprotein phosphorylation (VASP). The primary endpoint of the study is the inhibition of platelet aggregation (IPA) after arachidonic acid (AA) 0.5mM at 30 min. Secondary endopoints were the IPA at 1, 4, and 24 hours after AA, and non-AA pathways through the sequence (ADP and TRAP).<\/p>\n\n

Results.<\/em><\/strong> A total of 32 STEMI patients were randomized (16 LA, 16 aspirin). The inhibition of platelet aggregation after AA 0.5mM at 30 min was greater in subjects treated with LA compared with aspirin: 166 vs. 412 respectively (p = 0.001). This differential effect was observed at 1 hour (p 0 0.01), but not at 4 and 24 hours. Subjects treated with LA presented less variability and faster and greater inhibition of platelet aggregation wit AA compared with aspirin.<\/p>\n\n

Conclusion.<\/em><\/strong> The administration of intravenous LA resulted in a significantly reduction of platelet reactivity compared to oral aspirin on ticagrelor inhibited platelets in patients with STEMI. Loading dose of LA achieves an earlier platelet inhibition, and with less variability than aspirin.<\/p>\n\n

Bibliography<\/p>\n\n